Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 3
---
 CAN FIND MORE INFORMATION                            |  171 |

<div align='center'>ABOUT THIS PROSPECTUS</div>

This
prospectus is part of a registration statement on Form F-1 that we filed with the SEC whereby the Selling Shareholder named
herein may, from time to time, sell the securities offered by it described in this prospectus. We will not receive any proceeds from the
sale by such Selling Shareholder of the securities offered by it described in this prospectus.

Neither
we nor the Selling Shareholder has authorized anyone to provide you with any information or to make any representations other than those
contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or
to which we have referred you. Neither we nor the Selling Shareholder take responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. Neither we nor the Selling Shareholder will make an offer to sell these
securities in any jurisdiction where such offer or sale is not permitted. No dealer, salesperson or other person is authorized to give
any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing
prospectus. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate as of the date
on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or
any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.

The
Selling Shareholder and its permitted transferees may use this registration statement to sell securities from time to time through any
means described in the section titled “Plan of Distribution.” More specific terms of any securities that the Selling
Shareholder and its permitted transferees offer and sell may be provided in a prospectus supplement that describes, among other things,
the specific amounts and prices of the securities being offered and the terms of the offering.

We
may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or
change information contained in, this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained in such prospectus supplement or post-effective amendment modifies
or supersedes such statement.